ArticleThe AAPS journal2015
Human Health Relevance of Pharmaceutically Active Compounds in Drinking Water.
Article in The AAPS journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Incorporating a Screening-Level Risk Quotient (RQ_screen) for Assessing Human Health Risk of Pharmaceutical Residues in Consumption Water.International journal of environmental research and public health · 2026Pooled it
- Multi-Residue Determination and Risk Assessment of EU-Relevant Pharmaceuticals, Pesticides, and UV-Filters in Drinking Water.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Contaminants of Emerging Concern in Tomatoes Grown in Sludge-Amended Peat: Uptake, Translocation and Risk Assessment.Toxics · 2025Article
- Article
- Pharmaceuticals in raw and treated water from drinking water treatment plants nationwide: Insights into their sources and exposure risk assessment.Water research X · 2024Article
- Facile Synthesis of g-CNanomaterials (Basel, Switzerland) · 2021Article
- Pharmaceuticals in source waters of 95 First Nations in Canada.Canadian journal of public health = Revue canadienne de sante publique · 2021Article
- Diclofenac Degradation-Enzymes, Genetic Background and Cellular Alterations Triggered in Diclofenac-Metabolizing StrainInternational journal of molecular sciences · 2020Article
- Features of diclofenac biodegradation by Rhodococcus ruber IEGM 346.Scientific reports · 2019Article
- Abiotic degradation and environmental toxicity of ibuprofen: Roles of mineral particles and solar radiation.Water research · 2018Article
- Metformin in Reproductive Biology.Frontiers in endocrinology · 2018Review
- Evaluation of the National Return of unwanted medicines (RUM) program in Australia: a study protocol.Journal of pharmaceutical policy and practice · 2017Article
- Approaches to the Development of Human Health Toxicity Values for Active Pharmaceutical Ingredients in the Environment.The AAPS journal · 2016Review
- Pharmaceuticals and personal care products in waters: occurrence, toxicity, and risk.Environmental chemistry letters · 2015Article
- Environmental life cycle of fentanyl: From the cradle to an unknown grave.Journal of environmental qualityReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In Canada, as many as 20 pharmaceutically active compounds (PhACs) have been detected in samples of treated drinking water. The presence of these PhACs in drinking water raises important questions as to the human health risk posed by their potential appearance in drinking water supplies and the extent to which they indicate that other PhACs are present but have not been detected using current analytical methods. Therefore, the goal of the current investigation was to conduct a screening-level assessment of the human health risks posed by the aquatic release of an evaluation set of 335 selected PhACs. Predicted and measured concentrations were used to estimate the exposure of Canadians to each PhAC in the evaluation set. Risk evaluations based on measurements could only be performed for 17 PhACs and, of these, all were found to pose a negligible risk to human health when considered individually. The same approach to risk evaluation, but based on predicted rather than measured environmental concentrations, suggested that 322 PhACs of the evaluation set, when considered individually, are expected to pose a negligible risk to human health due to their potential presence in drinking waters. However, the following 14 PhACs should be prioritized for further study: triiodothyronine, thyroxine, ramipril and its metabolite ramiprilat, candesartan, lisinopril, atorvastatin, lorazepam, fentanyl, atenolol, metformin, enalaprilat, morphine, and irbesartan. Finally, the currently available monitoring data for PhACs in Canadian surface and drinking waters was found to be lacking, irrespective of whether their suitability was assessed based on risk posed, predicted exposure concentrations, or potency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.